News

FDA approves new treatment for rare form of hemophilia

On October 23, 2014, the U.S. Food and Drug Administration approved Obizur [Antihemophilic Factor (Recombinant), Porcine Sequence] for the treatment of bleeding episodes in adults with acquired hemophilia A (acquired Factor VIII [FVIII] deficiency).

FDA approves new treatment for rare form of hemophilia - Read More…

FDA approves Baxter's RIXUBIS for treatment of children with hemophilia B

On September 12, 2014, the United States Food and Drug Administration (FDA) approved Baxter International Inc.'s RIXUBIS for routine prophylactic treatment, control and prevention of bleeding episodes, and perioperative management in children with hemophilia B.

FDA approves Baxter's RIXUBIS for treatment of children with hemophilia B - Read More…

Nigel Key assumes chairmanship of the ISTH Council

Nigel Key, MD, Director of the UNC Hemophilia and Thrombosis Center, transitioned from the position of Chairman-Elect of the International Society on Thrombosis and Haemostasis Council to the role of Chairman at the ISTH Council meeting in Milwaukee June 23-26, 2014. Dr. Key's term will extend for two years.

Nigel Key assumes chairmanship of the ISTH Council - Read More…

U.S. FDA approves Biogen's hemophilia A drug Eloctate

On Friday, June 6, 2014, the U.S. Food and Drug Administration approved Eloctate, Antihemophilic Factor (Recombinant), Fc fusion protein, for use in adults and children who have hemophilia A. Eloctate is the first hemophilia A treatment designed to require less frequent injections when used to prevent or reduce the frequency of bleeding.

U.S. FDA approves Biogen's hemophilia A drug Eloctate - Read More…

New report released on CDC's Universal Data Collection program

The CDC established a national public health surveillance project called the Universal Data Collection (UDC) system, which was carried out by the CDC and federally funded hemophilia treatment centers (HTCs) from 1998 through 2011.

New report released on CDC's Universal Data Collection program - Read More…

U.S. FDA approves Biogen's hemophilia B drug Alprolix

Biogen Idec, Inc. has won U.S. approval for its long-acting hemophilia B treatment Alprolix, the U.S. Food and Drug Administration announced on Friday, March 28, 2014.

U.S. FDA approves Biogen's hemophilia B drug Alprolix - Read More…

Nigerian hematologist receives ISTH fellowship to study at UNC-Chapel Hill

Dr. Helen C. Okoye of Nigeria has received a Reach-the-World Fellowship offered by the International Society on Thrombosis and Haemostasis to receive training at the UNC-Chapel Hill Hemophilia & Thrombosis Center.

Nigerian hematologist receives ISTH fellowship to study at UNC-Chapel Hill - Read More…

UNC researchers create safe and effective synthetic blood thinner

The effects of this new low-molecular-weight synthetic heparin can be quickly reversed, unlike the effects of low-molecular-weight heparin currently in use.

UNC researchers create safe and effective synthetic blood thinner - Read More…

UNC hematologists listed in The Best Doctors in America 2014

UNC hematologists Nigel S. Key, Alice D. Ma, and Stephan Moll are included in the latest compilation of The Best Doctors in America database. Only five percent of doctors in America earn this honor, decided by impartial peer review.

UNC hematologists listed in The Best Doctors in America 2014 - Read More…

UNC hematologist Alice Ma, MD, part of the Choosing Wisely task force

Alice Ma, MD, from the UNC Division of Hematology/Oncology, was on the Choosing Wisely task force for the American Society of Hematology (ASH). ASH recently released a list of the five most common hematologic tests, treatments, and procedures that should be questioned by patients and physicians.

UNC hematologist Alice Ma, MD, part of the Choosing Wisely task force - Read More…

Article on hemophilic pseudotumors by UNC clinicians published by Haemophilia

An article entitled "Clinical features and management of haemophilic pseudotumours: a single US centre experience over a 30-year period" was published in the January 2014 issue of the journal Haemophilia. The authors are UNC clinicians Ming Y. Lim, MBBChir; Brenda Nielsen, MSN; Alice Ma, MD; and Nigel Key, MD.

Article on hemophilic pseudotumors by UNC clinicians published by Haemophilia - Read More…

Tretten approved for rare genetic clotting disorder

On December 23, the U.S. Food and Drug Administration approved Tretten (coagulation factor XIII A-subunit [recombinant]) for use in the routine prevention of bleeding in adults and children who have congenital Factor XIII A-subunit deficiency, a rare clotting disorder.

Tretten approved for rare genetic clotting disorder - Read More…

New gene therapy proves promising as hemophilia treatment

Researchers package specialized blood platelets with genes that express clotting factor, leading to fewer bleeding events.

New gene therapy proves promising as hemophilia treatment - Read More…

Registration opens for 7th UNC Symposium on Hemostasis May 2014

Registration is now open for the 7th UNC Symposium on Hemostasis, May 15-17, 2014, in Chapel Hill. The symposium is entitled "Old System, New Players, New Directions."

Registration opens for 7th UNC Symposium on Hemostasis May 2014 - Read More…

UNC TarHealers walk to raise money for Hemophilia of North Carolina

UNC TarHealers walk to raise money for Hemophilia of North Carolina

The UNC TarHealers walking team raised $1,675 for Hemophilia of North Carolina, the state chapter of the National Hemophilia Foundation.

UNC TarHealers walk to raise money for Hemophilia of North Carolina - Read More…

Clot Connect program featured on CNN

The Clot Connect program was featured prominently in an "Impact Your World" segment on CNN and Headline News.

Clot Connect program featured on CNN - Read More…

Charlene Cowell named as Hemophilia of North Carolina's new Executive Director

On September 27, 2013, Hemophilia of North Carolina Board President Steve Peretti announced that Charlene Cowell has been named as HNC's new Executive Director effective September 19.

Charlene Cowell named as Hemophilia of North Carolina's new Executive Director - Read More…

UNC TarHealers team to raise money at October 11 Hemophilia Walk

Faculty and staff members from UNC-Chapel Hill have formed the UNC TarHealers team to raise funds at the 2014 Hemophilia Walk in Morrisville, NC on Saturday, October 11, 2014.

UNC TarHealers team to raise money at October 11 Hemophilia Walk - Read More…